SEC Form 4 · accession 0001179110-17-010666

ABBOTT LABORATORIES · ABT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior Vice President

Period of report

Jul 21, 2017

Accepted (ET)

Jul 25, 2017 · 6:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000001800

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common shares without par value^F1	Jul 21, 2017	A	6,028	$0.00	A	56,187	D
Common shares without par value^F2	Jul 21, 2017	A	10,000	$0.00	A	66,187	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Option (right to buy)^F3	$50.72	Jul 21, 2017	A	69,024	A	Jul 21, 2018	Jul 20, 2027	Common shares	69,024	69,024	D

F1These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
F2These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, vesting in annual increments of 3,334 on 07/21/2018, 3,333 on 07/21/2019, and 3,333 on 07/21/2020. The awards include the right to have stock withheld for tax purposes.
F3Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,008 on 07/21/2018, 23,008 on 07/21/2019, and 23,008 on 07/21/2020.